Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
336.89M | 186.37M | 77.06M | 19.14M | 0.00 | Gross Profit |
255.25M | 139.34M | 64.69M | 17.23M | -623.00K | EBIT |
-87.61M | -109.15M | -131.22M | -173.41M | -104.30M | EBITDA |
-48.97M | -136.49M | -122.41M | -65.39M | -102.31M | Net Income Common Stockholders |
-87.94M | -163.41M | -135.66M | -83.99M | -103.27M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
280.31M | 286.33M | 251.72M | 156.54M | 231.82M | Total Assets |
670.75M | 646.62M | 352.91M | 294.65M | 240.86M | Total Debt |
317.76M | 308.14M | 2.19M | 2.61M | 3.26M | Net Debt |
95.26M | 21.82M | -25.82M | -28.73M | -138.82M | Total Liabilities |
445.11M | 397.95M | 210.87M | 174.44M | 68.77M | Stockholders Equity |
225.64M | 248.67M | -392.82M | 120.21M | -173.17M |
Cash Flow | Free Cash Flow | |||
9.33M | -91.05M | -120.41M | -151.78M | -89.30M | Operating Cash Flow |
10.32M | -70.94M | -120.14M | -132.76M | -89.08M | Investing Cash Flow |
-90.13M | -107.20M | 7.70M | 48.55M | 37.87M | Financing Cash Flow |
17.70M | 336.60M | 109.09M | 73.47M | 181.29M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $2.09B | 1,092.91 | 1.13% | ― | 14.80% | 530.21% | |
67 Neutral | $2.84B | ― | -32.17% | ― | -25.85% | -23.89% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
53 Neutral | $2.24B | ― | -33.06% | ― | 69.31% | 57.12% | |
45 Neutral | $1.70B | ― | -38.04% | ― | -82.38% | -164.76% | |
41 Neutral | $3.12B | ― | -30.57% | ― | ― | -147.80% | |
40 Underperform | $1.56B | ― | -30.29% | ― | ― | 7.97% |
On May 29, 2025, Mirum Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class III directors to serve until 2028, ratified Ernst & Young LLP as the independent public accounting firm for 2025, and approved executive compensation, indicating continued support for the company’s leadership and strategic direction.
The most recent analyst rating on (MIRM) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.